Drug Type Small molecule drug |
Synonyms AP 1189, AP-1189 |
Target |
Mechanism MC1R agonists(Melanocortin receptor 1 agonists), MC3R agonists(Melanocortin receptor 3 agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC16H18N6O4 |
InChIKeyFIESOFUABUPMMH-WAJHRQJSSA-N |
CAS Registry1809420-72-1 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Inflammation | Phase 2 | US | 01 Oct 2024 | |
Nephrotic Syndrome | Phase 2 | SE | 30 Jan 2022 | |
Respiratory Distress Syndrome, Adult | Phase 2 | SE | 30 Jan 2022 | |
Idiopathic Membranous Glomerulonephritis | Phase 2 | DK | 31 Aug 2020 | |
Infantile multisystem neurologic-endocrine-pancreatic disease | Phase 2 | DK | 31 Aug 2020 | |
Proteinuria | Phase 2 | DK | 31 Aug 2020 | |
Rheumatoid Arthritis | Phase 2 | DK | 26 Aug 2019 | |
Rheumatoid Arthritis | Phase 2 | NO | 26 Aug 2019 |
Phase 2 | 105 | (50 mg AP1189) | rrwuizrbem(wsnroxifyu) = nzdkubcvip tldgfkncwh (kmkxcsjxqd, wvsvhiviks - qedbhocsnr) View more | - | 10 Jul 2024 | ||
(100 mg AP1189) | rrwuizrbem(wsnroxifyu) = dxcbldritl tldgfkncwh (kmkxcsjxqd, egtwtmmqdp - yycwvmfmjy) View more |